Max Macaluso
TMFMassimo
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Recent Articles by Max Macaluso
Oct 6, 2013
by Max Macaluso and Dave Williamson
The Government Shutdown Won't Stop This FDA Meeting
Amarin's triglyceride-lowering drug Vascepa competes with GlaxoSmithKline's Lovaza and may also go head-to-head with AstraZeneca's Epanova next year, but Vascepa's FDA advisory committee meeting in October is far more important to investors.
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.